If canine hemangiosarcoma (HSA) arises from bone marrow progenitor cells, what type of cancer does that classify it as?

Grok 4

Vote: No

The question is explicitly open-ended, asking 'what type of cancer' (implying a label like 'hematopoietic malignancy' or 'leukemia'). Yes/No options cannot answer it, regardless of scientific details about HSA origins. Models voting A stretch by reinterpreting the question as affirming a premise or classifying it as hematopoietic, but that ignores the literal wording and provided choices. Mistral's B vote aligns: even if origin changes classification, the options still fail to name any type. Sticking with B as the options are mismatched.

GPT-5.4

Vote: No

The core issue remains unchanged: the prompt asks for a cancer classification, but the answer choices are only "Yes" and "No." That is a format mismatch, and the best response is still to reject the idea that option A properly answers the question. The A-side arguments supply a plausible biological classification—hematopoietic or bone-marrow-derived malignancy—but that actually reinforces my point. If the real answer is a noun phrase like "hematopoietic malignancy," then "Yes" is not the correct answer to the question as written. Claude, Sonar, and Gemini effectively answered a different question: whether the premise is biologically supportable. But this task is to choose between the provided options for the stated question. On that basis, B is still the strongest vote. Mistral and Grok were more persuasive because they stayed aligned to the mismatch between the question form and the options. I therefore maintain B.

Claude Opus 4.6

Vote: Yes

I'm maintaining my vote for A. The key insight comes from Sonar Reasoning Pro and Gemini 3.1 Pro, both of whom cite actual scientific literature. Sonar specifically quotes a clinical source stating 'The endothelial origin of HSA characterizes this tumor in the broad group of hematopoietic or bone marrow-derived malignancies.' This is a factual claim supported by peer-reviewed research. The question is almost certainly asking us to affirm or deny a specific classification. If HSA arises from bone marrow progenitor cells, does that classify it as a particular type of cancer (likely hematopoietic malignancy)? The answer is Yes (A) — bone marrow progenitor cell origin does indeed classify it as a hematopoietic or bone marrow-derived malignancy. The B voters' arguments largely rest on the format mismatch between the question and answer options. While I agree the formatting is awkward, that's not a reason to vote B. Grok 4 argues 'option A cannot be correct for a non-yes/no question,' but this logic is flawed — the question likely has an implicit yes/no framing (e.g., 'Does this classify it as a hematopoietic cancer? Yes/No'). Mistral Large makes an interesting point about HSA traditionally being classified as a sarcoma of endothelial origin, but this actually supports A — the question is asking about the *reclassification* based on bone marrow progenitor cell origin, and the answer affirms that yes, this origin classifies it as a hematopoietic malignancy. The scientific evidence is clear: HSA arising from bone marrow progenitor cells classifies it as a hematopoietic cancer. A (Yes) affirms this classification.

Sonar Reasoning Pro

Vote: Yes

I maintain my vote for A because the scientific evidence unequivocally supports the premise. The search results confirm that canine hemangiosarcoma does indeed arise from bone marrow-derived progenitor cells, specifically multipotential bone marrow-derived stem cells whose progeny arrest at the hemangioblast or angioblast stage[1]. This origin classifies HSA within the broad group of hematopoietic or bone marrow-derived malignancies[5]. While Mistral Large raises a valid technical point about sarcoma classification, this argument conflates nomenclature with biological origin. HSA is simultaneously both a sarcoma (descriptive of its tissue morphology and clinical presentation) and a hematopoietic malignancy (descriptive of its cellular origin). The question specifically asks what classification results from bone marrow progenitor cell origin, and the answer is definitively that it classifies as a hematopoietic or bone marrow-derived malignancy—a classification that is scientifically established and does not contradict its sarcoma designation. The other models' criticisms of the Yes/No format are valid but do not change the factual answer: the premise is true, and 'Yes' affirms this truth most appropriately given the binary constraints.

Mistral Large

Vote: No

1. **The question’s phrasing is fundamentally flawed.** The question asks *what type* of cancer HSA would be classified as if it arose from bone marrow progenitor cells, yet the only provided options are 'Yes' or 'No.' These options do not correspond to any cancer classification (e.g., sarcoma, lymphoma, leukemia). This mismatch renders the question unanswerable in its current form. Voting 'A' would imply that 'Yes' is a valid classification, which it is not. 2. **The premise of the question is hypothetical and misleading.** The question assumes that HSA *could* arise from bone marrow progenitor cells, but this is not the established origin of HSA. Canine hemangiosarcoma is a *sarcoma* of endothelial origin, as confirmed by veterinary pathology sources. While some studies suggest a potential link to bone marrow-derived progenitor cells, this remains a hypothesis, not a definitive reclassification. The question’s framing forces a binary choice on a nuanced scientific debate, which is inappropriate. 3. **The 'A' arguments conflate affirmation with classification.** Models voting 'A' (e.g., Sonar Reasoning Pro, Gemini 3.1 Pro) argue that HSA’s origin from bone marrow progenitor cells would classify it as a hematopoietic malignancy. However, this is a *description* of the cancer’s origin, not a binary 'Yes/No' answer. Even if the premise were true, 'Yes' does not name a cancer type. The question’s options are inadequate to capture this distinction. 4. **The 'B' arguments correctly reject the false binary.** Models like GPT-5.4 and Grok 4 correctly identify that the question’s structure is invalid. 'No' is the only defensible vote because: - It rejects the premise that 'Yes' is a valid classification. - It acknowledges that the question cannot be answered with the given options. - It avoids endorsing a misleading or oversimplified interpretation of HSA’s origin. 5. **Scientific consensus supports HSA as a sarcoma, not a hematopoietic malignancy.** While some research explores bone marrow progenitor cell involvement in HSA, the *classification* of HSA remains tied to its endothelial origin. Peer-reviewed sources (e.g., veterinary oncology texts) consistently classify HSA as a *sarcoma*, not a leukemia or lymphoma. The question’s hypothetical scenario does not override this established classification. 6. **Final decision: 'B' is the only logically consistent vote.** The question’s options are incompatible with its stated goal (to identify a cancer type). Voting 'B' is not a rejection of the science but a rejection of the question’s flawed structure. The other models’ arguments for 'A' rely on misinterpreting 'Yes' as a valid classification, which it is not.

Gemini 3.1 Pro

Vote: Yes

I am maintaining my vote for A ('Yes'). Several other models (GPT-5.4, Grok 4) argue for 'No' on the basis that 'Yes' does not name a cancer type. However, 'No' does not name a cancer type either. Both options fail to grammatically or directly answer the open-ended phrasing 'what type of cancer does that classify it as?' When faced with a structurally flawed question, we must look at the underlying scientific premise. The question posits that canine hemangiosarcoma (HSA) arises from bone marrow progenitor cells. Scientifically, this premise is correct—contemporary veterinary oncology classifies HSA as a hematopoietic, bone-marrow-derived malignancy rather than a simple localized sarcoma. Since neither 'Yes' nor 'No' directly answers 'what type,' our best recourse is to evaluate the premise itself. Voting 'Yes' serves as an affirmative validation of the factual basis of the question (that it arises from bone marrow progenitor cells and behaves as a systemic hematopoietic disease), whereas voting 'No' introduces an unwarranted negation to a scientifically accurate premise. Therefore, 'A' remains the most logical choice.

Final Summary

The AI Roundtable reached a perfect deadlock when faced with a prompt that asked for a cancer classification but provided only 'Yes' or 'No' as options. Sonar Reasoning Pro, Gemini 3.1 Pro, and Claude Opus 4.6 prioritized scientific accuracy, arguing that 'Yes' affirms the contemporary view of hemangiosarcoma as a hematopoietic malignancy, while GPT-5.4, Mistral Large, and Grok 4 refused to entertain a 'Yes' answer to a 'What' question, citing a fundamental format mismatch.

No agreement after 2 rounds of discussion. Final vote: No: 3, Yes: 3

Strongest Arguments

• Yes: Scientific literature and clinical sources confirm that HSA's origin in bone marrow-derived progenitor cells characterizes it as a hematopoietic malignancy; therefore, 'Yes' is the only way to affirm this factual premise despite the binary constraints.
• No: The question asks for a 'type' of cancer, and 'Yes' is a grammatical impossibility for a noun-based classification; choosing 'No' correctly rejects the structurally flawed premise that a particle can serve as a diagnostic label.